What Progyny Shareholders Got Right

Progyny’s year was punctuated by one concrete move: a US$200 million share repurchase that shrank the share count and signalled management’s confidence in the fertility benefits model. For Progyny shareholders, the return from the start of the year was 35.4%, including dividends. If you were weighing a purchase back on 2026-01-01, what did you need to believe about delayed parenthood and employer demand before any of that news crossed the wire?

If the move has made Progyny harder to judge, start where the gap is still open and scan 39 high quality undervalued stocks.

The Two Stories Progyny Investors Were Weighing

Progyny shares cost US$25.68 at the start of the period, so you were paying real money to pick a side in a genuine debate about delayed parenthood and employer benefits.

The bullish story pointed to a Fair Value of US$30.25, a rough guide to what that camp thought the stock was worth. This view was backed by expectations that insurers and large employers would treat Progyny as an essential fertility benefits platform.

The more cautious view put Fair Value at US$21. This perspective was built around the risk that tighter US healthcare policies and a shift toward gig work would shrink the pool of employees eligible for rich fertility coverage.

What The Progyny Results Actually Tested

Progyny’s Q3 2026 report showed revenue of US$341.3 million and net income of US$26.3 million, with net margin at 7.7% versus 4.4% a year earlier. That margin lift supported the optimistic case that employer-backed fertility benefits can support improving profitability. The cautious view stayed alive because investors still had to factor in policy risk and shifts toward gig work. Overall, the evidence cut both ways.

The lesson is simple. When a thesis hinges on employer demand and policy, track covered lives, client counts, and reported net margin, and then test them against what management claimed before you buy in.

What Progyny’s Price Already Assumes After A 35% Run

Progyny trades at US$34.84 today. This Narrative’s Fair Value sitting below that level frames the current quote as baking in a lot of execution on the fertility benefits story.

The Narrative hangs on whether Progyny can turn employer interest, high retention and platform spending into durable earnings quality and unit growth at this higher price.

"The main thing that has to go right is that Progyny converts strong employer interest in comprehensive women's health benefits, high client retention, and expanding carrier partnerships into sustained growth from new covered lives and brownfield wins while managing elevated platform investment."

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

How Could You Get There Earlier?

By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.

• Company 1 - 49% below our estimate - runs an asset-light hotel network while scaling a higher margin retail ecosystem.
• Company 2 - 19% below our estimate - sells security appliances powered by custom chips and a unified operating system.
• Company 3 - 40% below our estimate - handles freight forwarding where AI related cargo and compliance workloads are rising.

Three companies from the same screener. Open the full list of 24 financially solid companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com